AscellaHealth has ranked second on the Philadelphia Business Journal’s 2023 “Soaring 76” list of fastest-growing companies in Greater Philadelphia and first for fastest-growing private company, as measured by revenue over a three-year period from 2020 through 2022. This is the Company’s fourth time making the list, with innovative end-to-end solutions for patients, pharmaceutical manufacturers, payers and providers driving growth as an increasing number of clients choose to partner with AscellaHealth to streamline commercialization of specialty and rare disease products, increase access to specialty medications, improve patient outcomes and enhance client savings.
“We are deeply gratified to rank at the top of the ‘Soaring 76’ list including being named the fastest-growing private company in Greater Philadelphia and attribute this outstanding achievement to the dedication, expertise and hard work of our entire team,” says Dea Belazi, president and CEO, AscellaHealth. “The awards are testament to the relevant and timely differentiated value we provide to the market, supporting all specialty pharmacy and rare disease stakeholders with customized end-to-end solutions that optimize patient outcomes by providing a rare and special perspective, addressing unmet market and client needs.”
Every year, the Philadelphia Business Journal ranks the fastest-growing companies in the area based on Securities and Exchange Commission filings and honors recipients at an awards event where the ranking of each company is revealed. To determine the list, the Business Journal sought online nominations from private companies. Those that met this year’s parameters were then vetted through a process that included the Business Journal editorial board and accounting partner for this year, CLA. In addition to private companies, publicly traded companies that met the same parameters were added to the final list. Listmakers are required to be headquartered in Greater Philadelphia, be independently owned without a parent company, have sustained revenue growth from 2020-2022, and a minimum revenue of $750,000 in 2020.
“Increased revenues are indicative of marketplace confidence in our business approach and growing portfolio of uniquely tailored solutions serving all industry stakeholders, including our biotech/pharma and payer clients,” Belazi adds. “We are thrilled to be included among these successful, dynamic organizations throughout the region. This distinction belongs to the entire AscellaHealth team, which reflects deep bench knowledge and strategic industry expertise. They are truly innovators and their work yields measurable results to fulfill the unmet needs of our patients and partners.”
About AscellaHealth LLC
AscellaHealth, a global healthcare and specialty pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies. A recipient of numerous industry awards for innovation, including Deloitte Technology Fast 500™ and Inc. 5000, AscellaHealth’s customized, patient-centric approach is built upon proprietary technology processes for end-to-end solutions to streamline the commercialization of specialty medications and proactively address unmet client needs, optimize clinical health outcomes and improve the quality of life for this patient population. AscellaHealth brings a rare and special perspective to all stakeholders.
Source link : https://www.businesswire.com/
